BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is set to report quarterly earnings on 8/7/2017 8:30:00 AM. For the last period, the company reported quarter over quarter EPS growth of 39.00% and quarter over quarter sales growth of 95.80%.
Heading into the earnings release, covering analysts have a consensus target price of $8.63 on BioCryst Pharmaceuticals, Inc. shares. After a recent check, company stock has been trading near the $5.10 mark.
Sell-side analysts have also provided a consensus recommendation of 2.40 on company shares. Investors will be eagerly watching to see if the firm beats or misses on the earnings front.
Depending on the earnings numbers reported, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock may see increased volatility following the report. In terms of recent volatility, the average for the month is 4.65% and 5.48% for the past week. The relative volume (ratio between current volume and 3-month average) is presently sitting at 0.40.
Since the start of the New Year, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares have seen a move of -19.43%. Looking back over the last month, shares have performed -10.05%. For the past 5 days of trading, the stock has seen a move of -3.23%.
Let’s also take a brief look at the stock price in relation to some highs/lows and moving averages. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares have been recently spotted -44.86% away from the 52-week high, and 36.00% away from the 52-week low mark. After a recent look, shares have been seen -16.42% from the 200-day moving average, and -8.29% from the 50-day moving average. The stock’s current RSI reading is at 42.29.
As the earnings date approaches, we can see that insider ownership is currently 0.40% shares, and institutional ownership is at 87.50% for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock. Over the past few months, insider ownership has seen a move of -4.96% while institutional ownership has changed 3.26%.